Synopsis
Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3,5,3',5'-tetraiodothyronine
2. Berlthyrox
3. Dexnon
4. Eferox
5. Eltroxin
6. Eltroxine
7. Euthyrox
8. Eutirox
9. L Thyrox
10. L Thyroxin Beta
11. L Thyroxin Henning
12. L Thyroxine
13. L Thyroxine Roche
14. L-3,5,3',5'-tetraiodothyronine
15. L-thyrox
16. L-thyroxin Beta
17. L-thyroxin Henning
18. L-thyroxine
19. L-thyroxine Roche
20. Lvothyrox
21. Levo T
22. Levo-t
23. Levothroid
24. Levothyroid
25. Levothyroxin Deladande
26. Levothyroxin Delalande
27. Levothyroxine
28. Levothyroxine Sodium
29. Levoxine
30. Levoxyl
31. Novothyral
32. Novothyrox
33. O-(4-hydroxy-3,5-diiodophenyl) 3,5-diiodo-l-tyrosine
34. O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine
35. Oroxine
36. Sodium Levothyroxine
37. Synthroid
38. Synthrox
39. T4 Thyroid Hormone
40. Thevier
41. Thyrax
42. Thyroid Hormone, T4
43. Thyroxin
44. Thyroxine
45. Tiroidine
46. Tiroxina Leo
47. Unithroid
1. 25416-65-3
2. Levothyroxine Sodium
3. L-thyroxine Sodium Xhydrate
4. Levothyroxine Sodium Hydrate
5. L-thyroxine Sodium Hydrate
6. Monosodium L-thyroxine Hydrate
7. 31178-59-3
8. Chebi:6447
9. Levothroid
10. Synthroid
11. Levothyrox
12. Levaxin
13. Levoxyl
14. Oroxine
15. Soloxine
16. Eferox
17. Sodium;(2s)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;hydrate
18. B82379r9w0
19. Thyroxine Sodium
20. Levo-t
21. Liotrix (t4)
22. Thyroxine Sodium Salt
23. L-tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, Monosodium Salt, Monohydrate
24. Latequatro
25. Letequatro
26. Levoroxin
27. Levotiron
28. Tiroxina
29. Tivoral
30. Levo-tiroxina Glaxo
31. Nsc-259940
32. L-tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, Monosodium Salt, Hydrate
33. Unii-b82379r9w0
34. Levothroid (tn)
35. Synthroid (tn)
36. Levoxyl (tn)
37. Levothyroxine Sodium [usp:inn:jan]
38. Starbld0009614
39. L-thyroxin Monosodium Salt
40. T4 (liotrix)
41. Levothyroxine Sodium (usp)
42. Schembl2327406
43. Chembl2103741
44. L-thyroxine Sodium Salt Monohydrate
45. 3,3',5,5'-tetraiodo-l-thyronine Monosodium Salt Hydrate
46. Levothyroxine Sodium Hydrate (jp17)
47. Mfcd06408007
48. Akos015895962
49. Ks-1237
50. D01010
51. E78443
52. Levothyroxine Sodium Monohydrate [who-ip]
53. 3,3',5,5'-tetraiodo-l-thyronine Monosodium Salt
54. A817851
55. Q27107209
56. Levothyroxinum Natricum Monohydrate [who-ip Latin]
57. Sodium 2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]propanoate Hydrate
58. Sodium (s)-2-amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)propanoate Xhydrate
Molecular Weight | 816.87 g/mol |
---|---|
Molecular Formula | C15H12I4NNaO5 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 5 |
Exact Mass | 816.6792 g/mol |
Monoisotopic Mass | 816.6792 g/mol |
Topological Polar Surface Area | 96.6 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 426 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 8 | |
---|---|
Drug Name | Levo-t |
Drug Label | Levothyroxine sodium tablets, USP contains synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is identical to that produced in the human thyroid gland.Levothyroxine (T4) sodium has an empir |
Active Ingredient | Levothyroxine sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | 0.05mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.112mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.2mg **see current annual edition, 1.8 description of spe |
Market Status | Prescription |
Company | Alara Pharm |
2 of 8 | |
---|---|
Drug Name | Levothroid |
PubMed Health | Thyroid Supplement (By mouth) |
Drug Classes | Diagnostic Agent, Thyroid Function, Thyroid Supplement |
Drug Label | LEVOTHROID (levothyroxine sodium tablets, USP) contains synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is identical to that produced in the human thyroid gland. Levothyroxine (T4) sodiu |
Active Ingredient | Levothyroxine sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | 0.05mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.112mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.2mg **see current annual edition, 1.8 description of spe |
Market Status | Prescription |
Company | Lloyd |
3 of 8 | |
---|---|
Drug Name | Levothyroxine sodium |
Active Ingredient | Levothyroxine sodium |
Dosage Form | Tablet; Powder; Injectable |
Route | injection; Oral; Intravenous |
Strength | 0.05mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 200mcg/vial; 0.112mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.2mg **see current annual edition, 1.8 descr |
Market Status | Prescription |
Company | Fresenius Kabi Usa; Mylan |
4 of 8 | |
---|---|
Drug Name | Levoxyl |
Drug Label | LEVOXYL (levothyroxine sodium tablets, USP) contain synthetic crystalline L-3,3,5,5-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is identical to that produced in the human thyroid gland. Levothyroxine (T4) sodiu... |
Active Ingredient | Levothyroxine sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | 0.05mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.112mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.2mg **see current annual edition, 1.8 description of spe |
Market Status | Prescription |
Company | King Pharms R And D |
5 of 8 | |
---|---|
Drug Name | Levo-t |
Drug Label | Levothyroxine sodium tablets, USP contains synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is identical to that produced in the human thyroid gland.Levothyroxine (T4) sodium has an empir |
Active Ingredient | Levothyroxine sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | 0.05mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.112mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.2mg **see current annual edition, 1.8 description of spe |
Market Status | Prescription |
Company | Alara Pharm |
6 of 8 | |
---|---|
Drug Name | Levothroid |
PubMed Health | Thyroid Supplement (By mouth) |
Drug Classes | Diagnostic Agent, Thyroid Function, Thyroid Supplement |
Drug Label | LEVOTHROID (levothyroxine sodium tablets, USP) contains synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is identical to that produced in the human thyroid gland. Levothyroxine (T4) sodiu |
Active Ingredient | Levothyroxine sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | 0.05mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.112mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.2mg **see current annual edition, 1.8 description of spe |
Market Status | Prescription |
Company | Lloyd |
7 of 8 | |
---|---|
Drug Name | Levothyroxine sodium |
Active Ingredient | Levothyroxine sodium |
Dosage Form | Tablet; Powder; Injectable |
Route | injection; Oral; Intravenous |
Strength | 0.05mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 200mcg/vial; 0.112mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.2mg **see current annual edition, 1.8 descr |
Market Status | Prescription |
Company | Fresenius Kabi Usa; Mylan |
8 of 8 | |
---|---|
Drug Name | Levoxyl |
Drug Label | LEVOXYL (levothyroxine sodium tablets, USP) contain synthetic crystalline L-3,3,5,5-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is identical to that produced in the human thyroid gland. Levothyroxine (T4) sodiu... |
Active Ingredient | Levothyroxine sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | 0.05mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.112mg **see current annual edition, 1.8 description of special situations, levothyroxine sodium; 0.2mg **see current annual edition, 1.8 description of spe |
Market Status | Prescription |
Company | King Pharms R And D |
H - Systemic hormonal preparations, excl. sex hormones and insulins
H03 - Thyroid therapy
H03A - Thyroid preparations
H03AA - Thyroid hormones
H03AA01 - Levothyroxine sodium
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : RX
Registration Country : USA
Brand Name : SYNTHROID
Dosage Form : TABLET;ORAL
Dosage Strength : 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Packaging :
Approval Date : 2002-07-24
Application Number : 21402
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : SYNTHROID
Dosage Form : TABLET;ORAL
Dosage Strength : 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Packaging :
Approval Date : 2002-07-24
Application Number : 21402
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : SYNTHROID
Dosage Form : TABLET;ORAL
Dosage Strength : 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Packaging :
Approval Date : 2002-07-24
Application Number : 21402
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : SYNTHROID
Dosage Form : TABLET;ORAL
Dosage Strength : 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Packaging :
Approval Date : 2002-07-24
Application Number : 21402
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : SYNTHROID
Dosage Form : TABLET;ORAL
Dosage Strength : 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Packaging :
Approval Date : 2002-07-24
Application Number : 21402
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : SYNTHROID
Dosage Form : TABLET;ORAL
Dosage Strength : 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Packaging :
Approval Date : 2002-07-24
Application Number : 21402
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : SYNTHROID
Dosage Form : TABLET;ORAL
Dosage Strength : 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Packaging :
Approval Date : 2002-07-24
Application Number : 21402
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : SYNTHROID
Dosage Form : TABLET;ORAL
Dosage Strength : 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Packaging :
Approval Date : 2002-07-24
Application Number : 21402
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : SYNTHROID
Dosage Form : TABLET;ORAL
Dosage Strength : 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Packaging :
Approval Date : 2002-07-24
Application Number : 21402
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : SYNTHROID
Dosage Form : TABLET;ORAL
Dosage Strength : 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Packaging :
Approval Date : 2002-07-24
Application Number : 21402
Regulatory Info : RX
Registration Country : USA
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Levothyroxine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Levothyroxine, including repackagers and relabelers. The FDA regulates Levothyroxine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Levothyroxine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Levothyroxine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Levothyroxine supplier is an individual or a company that provides Levothyroxine active pharmaceutical ingredient (API) or Levothyroxine finished formulations upon request. The Levothyroxine suppliers may include Levothyroxine API manufacturers, exporters, distributors and traders.
click here to find a list of Levothyroxine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Levothyroxine DMF (Drug Master File) is a document detailing the whole manufacturing process of Levothyroxine active pharmaceutical ingredient (API) in detail. Different forms of Levothyroxine DMFs exist exist since differing nations have different regulations, such as Levothyroxine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Levothyroxine DMF submitted to regulatory agencies in the US is known as a USDMF. Levothyroxine USDMF includes data on Levothyroxine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Levothyroxine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Levothyroxine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Levothyroxine Drug Master File in Japan (Levothyroxine JDMF) empowers Levothyroxine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Levothyroxine JDMF during the approval evaluation for pharmaceutical products. At the time of Levothyroxine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Levothyroxine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Levothyroxine Drug Master File in Korea (Levothyroxine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Levothyroxine. The MFDS reviews the Levothyroxine KDMF as part of the drug registration process and uses the information provided in the Levothyroxine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Levothyroxine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Levothyroxine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Levothyroxine suppliers with KDMF on PharmaCompass.
A Levothyroxine CEP of the European Pharmacopoeia monograph is often referred to as a Levothyroxine Certificate of Suitability (COS). The purpose of a Levothyroxine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Levothyroxine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Levothyroxine to their clients by showing that a Levothyroxine CEP has been issued for it. The manufacturer submits a Levothyroxine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Levothyroxine CEP holder for the record. Additionally, the data presented in the Levothyroxine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Levothyroxine DMF.
A Levothyroxine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Levothyroxine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Levothyroxine suppliers with CEP (COS) on PharmaCompass.
A Levothyroxine written confirmation (Levothyroxine WC) is an official document issued by a regulatory agency to a Levothyroxine manufacturer, verifying that the manufacturing facility of a Levothyroxine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Levothyroxine APIs or Levothyroxine finished pharmaceutical products to another nation, regulatory agencies frequently require a Levothyroxine WC (written confirmation) as part of the regulatory process.
click here to find a list of Levothyroxine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Levothyroxine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Levothyroxine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Levothyroxine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Levothyroxine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Levothyroxine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Levothyroxine suppliers with NDC on PharmaCompass.
Levothyroxine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Levothyroxine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Levothyroxine GMP manufacturer or Levothyroxine GMP API supplier for your needs.
A Levothyroxine CoA (Certificate of Analysis) is a formal document that attests to Levothyroxine's compliance with Levothyroxine specifications and serves as a tool for batch-level quality control.
Levothyroxine CoA mostly includes findings from lab analyses of a specific batch. For each Levothyroxine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Levothyroxine may be tested according to a variety of international standards, such as European Pharmacopoeia (Levothyroxine EP), Levothyroxine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Levothyroxine USP).
LOOKING FOR A SUPPLIER?